Abstracts tagged "Systemic sclerosis"

Abstract Number: 0712 • ACR Convergence 2022
Disease Prevalence and Patient Characteristics in Patients with and Without Scleroderma Renal Crisis – A National US-based Inpatient Comparison Study
Anila Hussain¹, Pushti Khandwala² and Thais Moldovan³, ¹Crozer Chester Medical Center, Glen Mills, PA, ²Einstein Medical Center Philadelphia, Glen Mills, PA, ³Rheumatology Care Center, Media, PA
Background/Purpose: Scleroderma renal crisis is a rare complication of Systemic Sclerosis (SSc) with high mortality and morbidity. Most patients present with acute symptomatic increase in…
Abstract Number: 1173 • ACR Convergence 2022
Single-cell Multi-omic Analysis of a 3D Skin-Like Tissue Model Provides Insights into Molecular and Cellular Drivers of Systemic Sclerosis
Tamar Abel¹, Noelle Kosarek², Rezvan Parvizi³, Helen Jarnagin¹, Mengqi Huang⁴, Avi Smith⁵, Michael Mariani¹, Dillon Popovich⁶, Heetaek Yang⁷, Tammara Wood⁸, Jonathan Garlick⁹, Patricia Pioli⁷ and Michael Whitfield¹⁰, ¹Dartmouth College, Lebanon, NH, ²Dartmouth Geisel School of Medicine, Lebanon, NH, ³Dartmouth, Lebanon, NH, ⁴University of Pittsburgh, Pittsburgh, PN, ⁵Tufts University, Boston, MA, ⁶Dartmouth College, West Lebanon, NH, ⁷Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁸Dartmouth College, Hanover, NH, ⁹Tufts University School of Dental Medicine, Boston, MA, ¹⁰Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic Sclerosis (SSc) currently lacks reliable in vitro models of skin fibrosis constructed from all human cells. We have developed a skin-like tissue model of systemic…
Abstract Number: 1385 • ACR Convergence 2022
Clinical and Serologic Characterization of Juvenile Systemic Sclerosis Overlap Disease
Amanda Robinson and Kathryn Torok, Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a systemic fibroinflammatory autoimmune disease characterized by skin fibrosis and multiple extracutaneous manifestations. A proportion of children with jSSc…
Abstract Number: 1659 • ACR Convergence 2022
FAM13A (Family with Sequence Similarity 13 Member A) Polymorphism Is Associated with Presence of a Radiographic Usual Interstitial Pneumonia Pattern in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Elana Bernstein¹, Francesco Boin², Brett Elicker³, Yawen Ren⁴, John Varga⁵ and Shervin Assassi⁶, ¹Columbia University, New York, NY, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶McGovern Medical School, University of Texas, Houston, TX
Background/Purpose: The pathogenesis of SSc-associated interstitial lung disease (ILD) is incompletely understood. The MUC5B promoter gain-of-function single nucleotide polymorphism (SNP) rs35705950 has been associated with…
Abstract Number: 2175 • ACR Convergence 2022
Evaluation of the Distribution of Haemodynamic Parameters and Prognostic Impact in a Cohort of Patients with Systemic Sclerosis
Zoe Brown¹, Dylan Hansen², Wendy Stevens², Laura Ross¹, Nava Ferdowsi², Susanna Proudman³, Jenny Walker⁴, Jo Sahhar⁵, Gene-Siew Ngian⁶, Lauren Host⁷, Gabor Major⁸, Mandana Nikpour⁹ and Kathleen Morrisroe², ¹St Vincent's Hospital, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³University of Adelaide, Medindie, Australia, ⁴Flinders Medical Centre, Flinders University, Daw Park, Australia, ⁵Monash Health, Melbourne, Australia, ⁶Melbourne Health, Northcote, Australia, ⁷Fiona Stanley Hospital, London, United Kingdom, ⁸Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, ⁹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) is a complex multisystem autoimmune disease, characterised by vasculopathy and fibrosis of skin and organs. Involvement of the cardiovascular system occurs frequently…
Abstract Number: 0832 • ACR Convergence 2022
Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflammatory Conditions?
Paulo Vilas-Boas¹, Gisela Eugenio² and Anabela Barcelos², ¹Rheumatology Department, Centro Hospitalar Baixo Vouga, Aveiro, Portugal, ²Centro Hospitalar Baixo Vouga, Aveiro, Portugal
Background/Purpose: Anti-NOR 90 antibodies have been detected in inflammatory conditions, neoplastic diseases and even in healthy individuals. Despite numerous epidemiologic studies, large scale studies are…
Abstract Number: 1174 • ACR Convergence 2022
Cellular Immunotherapy for Systemic Sclerosis
Chanhyuk Park¹, Rajan Bhandari², Jason Gunn³, Timothy Sullivan², Gretel Torres², Joana Murad³, Michael Whitfield⁴ and Patricia Pioli², ¹Geisel School of Medicine at Dartmouth, West Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Celdara Medical, Lebanon, ⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Pro-fibrotic macrophages (MØs) are implicated in the pathogenesis of systemic sclerosis (SSc). In prior work, we and others have shown that MØs derived from…
Abstract Number: 1521 • ACR Convergence 2022
Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial)
Nadine Sarsam¹, Sindhu R. Johnson², Lorinda Chung³, Suzanne Kafaja⁴, Janet Pope⁵, Robyn Domsic⁶, Maureen Mayes⁷, Nora Sandorfi⁸, Virginia Steen⁹, Flavia Castelino¹⁰, Faye Hant¹¹, Suiyuan Huang¹ and Dinesh Khanna¹², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Stanford University, Stanford, CA, ⁴UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, ⁵University of Western Ontario, London, ON, Canada, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Georgetown University School of Medicine, Washington, DC, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Abatacept (ABA) is a cytotoxic T-lymphocyte-associated molecule-4 immunoglobulin fusion protein which has been shown to induce regression of dermal fibrosis in patients with systemic…
Abstract Number: 1660 • ACR Convergence 2022
Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality
Julie Paik¹, Caoilfhionn Connolly¹, Fredrick Wigley¹ and Laura Hummers², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Univerisity, Baltimore, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is poorly understood. The etiology of myopathy in SSc is heterogeneous and can result from an inflammation, disuse,…
Abstract Number: 2177 • ACR Convergence 2022
Familial Clustering of Systemic Sclerosis, Autoimmunity, and Cancer History
Mariana Bombini¹, Nailú Sinicato¹, Jacqueline Paredes², Theresa Wampler Muskardin², Tiago Nardi Amaral¹, Ana Paula Del Rio¹, Joao Marques Neto³, Timothy Niewold² and Simone Appenzeller⁴, ¹State University of Campinas, Campinas, São Paulo, Brazil, ²Hospital for Special Surgery, New York, NY, ³State University of Campinas, São Paulo, Brazil, ⁴Unicamp, Campinas, São Paulo, Brazil
Background/Purpose: Systemic sclerosis (SSc) is a complex disease characterized by chronic inflammation, fibrosis, and vasculopathy. Genetic factors contribute to pathogenesis, but because it is a…
Abstract Number: 0398 • ACR Convergence 2021
Performance of ACR CRISS Score and Revised ACR CRISS Response in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc) in Which Background Immunosuppressive Therapies (bIST) Were Allowed
Dinesh Khanna¹, Robert Spiera² and Barbara White³, ¹University of Michigan, Ann Arbor, MI, ²Hospital for Special Surgery, New York, NY, ³Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: ACR CRISS score is the probability of improvement from baseline in each participant (pt) ranging from 0 to 1 (no to high probability), based…
Abstract Number: 0543 • ACR Convergence 2021
Novel Insights into Systemic Sclerosis Using a Sensitive Computational Method to Analyze Whole-genome Bisulfite Sequencing Data
Jeffrey Yu¹, Tianyuan Lu¹, Kaiqiong Zhao¹, Kathleen Oros Klein¹, Maximilien Lora², Ines Colmegna³, Celia MT Greenwood⁴ and Marie Hudson², ¹Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Epidemiology, Biostatistics and Occupational Health / Faculty of Medicine and Health Sciences / McGill University, Montréal, QC, Canada
Background/Purpose: While the etiology of systemic sclerosis (SSc) remains largely unknown, epigenetic dysregulation including abnormal DNA methylation is thought to contribute to its onset and…
Abstract Number: 0847 • ACR Convergence 2021
A Psychometric Analysis of the Self-Efficacy for Managing Chronic Disease Scale in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
Alyssa Choi¹, Chelsea Rapoport², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Karen Gottesman⁵, Scott Roesch⁶, Brett Thombs⁷ and Vanessa Malcarne⁶, ¹SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, La Jolla, CA, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵Scleroderma Foundation, Southern California Chapter, Danvers, MA, ⁶SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology; Department of Psychology, San Diego State University, San Diego, CA, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Self-efficacy is a key determinant of health behaviors and the target mechanism of self-management programs for patients with chronic diseases. The Self-Efficacy for Managing…
Abstract Number: 1373 • ACR Convergence 2021
Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Yossra Suliman³, Mohamed Alemam⁴, Rosha Mamita⁵, Jennifer Wang⁵, Ani Shahbazian⁶, Philip Clements⁷ and Christina Charles-Schoeman⁶, ¹University of California Los Angeles Division of Rheumatology, Los Angeles, CA, ²Florida Universtity- College of Health and Human Sciences, Talahhasse, FL, ³Department of Clinical Pathology, Qena Faculty of Medicine, Assiut, Egypt, ⁴Department of Pathology< Qena Faculty of Medicine, South Valley University,, Assiut, Egypt, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA
Background/Purpose: Our understanding of the pathogenesis of systemic sclerosis (SSc) continues to evolve. Oxidative stress has been implicated in the pathophysiology of disease, but minimal…
Abstract Number: 1613 • ACR Convergence 2021
Pandemic and Patients: Examining Health-Related Behaviors of Patients with Systemic Sclerosis During the COVID-19 Pandemic
Nancy Dorr¹, Patricia Fennell² and Lee Shapiro³, ¹The College of Saint Rose, Albany, NY, ²Albany Health Management Associates, Inc. Steffens Scleroderma Foundation, Albany, NY, ³Albany Medical College, Stillwater, NY
Background/Purpose: Prior to COVID-19, few studies examined how patients with a chronic illness, such as systemic sclerosis (SSc), react to a pandemic. This study examined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.